What Aprea Therapeutics, Inc. does.

We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. We have assembled a team with extensive experience in the discovery, development, and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics.

Aprea Therapeutics AB was originally incorporated in 2002 and commenced principal operations in 2006. On September 20, 2019, we consummated a reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB were exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics, Inc. As a result, Aprea Therapeutics AB became a wholly-owned subsidiary of Aprea Therapeutics, Inc.

Revenue and profit, by fiscal year.

More on APRE.

• Aprea Therapeutics, Inc. summary
• Aprea Therapeutics, Inc. financial statements
• Aprea Therapeutics, Inc. key metrics
• Aprea Therapeutics, Inc. health scores and style box
• Aprea Therapeutics, Inc. earnings
• Aprea Therapeutics, Inc. dividends
• Aprea Therapeutics, Inc. valuation
• Aprea Therapeutics, Inc. ownership and insiders
• Aprea Therapeutics, Inc. peers

Figures from Aprea Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.